Looking back at lung cancer treatment: can adding a drug after standard care help control disease?
NCT ID NCT07309211
Summary
This study looks back at the medical records of 25 Chinese patients with limited-stage small cell lung cancer. It aims to see if adding the drug durvalumab after they completed standard chemotherapy and radiation (given one after the other) is safe and helps control the cancer. The main goal is to check for serious side effects, while also seeing if the treatment helps delay the cancer's return.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
-
Nanjing Chest Hospital
NOT_YET_RECRUITINGNanjing, China
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, China
-
The affiliated hospital of qingdao university
RECRUITINGQingdao, China
Conditions
Explore the condition pages connected to this study.